Qiagen has signed on two new partners to its microarray efforts, making Bayer an early access customer for its ZeptoGene Workstation microarray platform, and acquiring exclusive distribution rights to Genicon Sciences’ self-spotted microarray toolkit products, the company said.

In signing these agreements, Qiagen is endeavoring to cover both high and low ends of the microarray market, said Solveigh Mahler, manager of investor relations for Qiagen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.